NUVL Stock Price Chart
NUVL Financial
Nuvalent, Inc
$123.9
0.05%
$0.07
At close: Jul 10, 16:00:00 GMT-4
$123.94
0.03%
$0.03
Post-market: Jul 10, 20:00:00 GMT-4
Back
Nuvalent, Inc (NUVL) Financial
Key Stats
Prev.Close
$123.83
Open
$123.87
Day's Range
$123.83 - $123.95
52 week range
$71.13 - $123.94
Volume
2.0M
Avg.Volume
1.5M
Dividend yield
--
EPS (TTM)
-6.05
Market Cap
$9.8B
What is NUVL?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
